IOX THERAPEUTICS LTD.
iOx Therapeutics Ltd. operates as an immuno-oncology company. Founded in February 2015 by Professor Cerundolo, iOx Therapeutics is a spin-out from the University of Oxford started to commercialize discoveries made as part of a long-running collaboration between Oxford and the Ludwig Institute for Cancer Research. iOx intends to develop and commercialize multiple synthetic lipid compounds discovered by a research team led by Professor Cerundolo.
IOX THERAPEUTICS LTD.
Industry:
Biopharma Biotechnology Health Care Therapeutics
Founded:
2015-01-01
Address:
London, England, United Kingdom
Country:
United Kingdom
Total Employee:
1+
Status:
Active
Total Funding:
950 K USD
Similar Organizations
Context Therapeutics
Context Therapeutics is a clinical-stage biopharmaceutical company.
Werewolf Therapeutics
Werewolf Therapeutics operates as an oncology biotherapeutics company.
Current Employees Featured
Founder
Investors List
Portage Biotech
Portage Biotech investment in Convertible Note - iOx Therapeutics Ltd.
Horizon 2020
Horizon 2020 investment in Grant - iOx Therapeutics Ltd.
More informations about "iOx Therapeutics Ltd."
iOx Therapeutics Company Profile 2024: Valuation, Investors ...
IOx Therapeutics General Information Description. Developer of therapeutics designed to stimulate the immune system to fight cancer. The company focuses on developing cancer …See details»
IOX THERAPEUTICS LIMITED overview - Companies House
More for IOX THERAPEUTICS LIMITED (09430782) Registered office address The Broadgate Tower 8th Floor, 20 Primrose Street, London, England, EC2A 2EW . Company status Active …See details»
Ludwig Cancer Research and University of Oxford launch cancer ...
Oxford University Innovation, the University of Oxford’s technology commercialisation company, and Ludwig Cancer Research are proud to announce the launch of a new spinout company, …See details»
iOX Therapeutics Ltd. - Drug pipelines, Patents, Clinical trials
Explore iOX Therapeutics Ltd. with its drug pipeline, therapeutic area, technology platform, 1 clinical trial, 5 news, Disease Domain:Neoplasms, Technology Platform:Small molecule drug, …See details»
iOx Therapeutics teams with Portage on immunotherapies
Mar 9, 2018 iOx Therapeutics, an immunotherapy firm spun out by Oxford University Innovation (OUI) in 2015, has received $950,000 from drug discovery investment firm Portage Biotech. …See details»
iOx Therapeutics Ltd - Company Profile and News
Company profile page for iOx Therapeutics Ltd including stock price, company news, executives, board members, and contact informationSee details»
iOx Therapeutics - Products, Competitors, Financials, Employees ...
About iOx Therapeutics. iOx Therapeutics is a spin-out from the University of Oxford started to commercialize discoveries made as part of a long-running collaboration between Oxford and …See details»
iOx Therapeutics Ltd. - Funding, Financials, Valuation & Investors
Their latest funding was raised on Mar 8, 2018 from a Convertible Note round. iOx Therapeutics Ltd. is funded by 2 investors. Portage Biotech and Horizon 2020 are the most recent investors. …See details»
iOx Therapeutics Ltd. - Crunchbase
IOx Therapeutics Ltd. operates as an immuno-oncology company.See details»
iOX Therapeutics Launched by Ludwig Cancer Research and …
Jul 15, 2015 The University of Oxford’s commercialization company, Isis Innovation, together with the Ludwig Cancer Research have just announced the official launch of a new company, …See details»
Portage Biotech Acquires Outstanding Minority Interest of
Jul 20, 2022 The platform was acquired through Portage’s iOx Therapeutics Ltd. (iOx) subsidiary from the founding equity holders in exchange for 1,070,000 ordinary shares of Portage. …See details»
Portage invests in iOx Therapeutics, an United Kingdom-based …
Mar 8, 2018 Founded in February 2015 by Professor Cerundolo, iOx Therapeutics is a spin-out from the University of Oxford started to commercialize discoveries made as part of a long …See details»
Portage Biotech Acquires Outstanding Minority Interest of …
Jul 20, 2022 Portage now holds 100% ownership of iOx Therapeutics Ltd., buying out remainder of equity in exchange for PRTG stockWESTPORT, Conn., July 20, 2022 (GLOBE …See details»
NEWS RELEASE PORTAGE INVESTS IN IOX THERAPEUTICS, AN …
Investment in iOx Therapeutics, Ltd. (“iOx”), a United Kingdom-based immuno-oncology company. Portage will invest US$950,000 by subscribing to an unsecured, one-year convertible loan …See details»
Ludwig Cancer Research And University of Oxford Launch Cancer ...
Jul 9, 2015 Isis Innovation, the University of Oxford’s technology commercialisation company, and Ludwig Cancer Research are proud to announce the launch of a new spinout company, …See details»
iOx Therapeutics Ltd. - BioCentury Company Profiles - BCIQ
IOx Therapeutics Ltd. - BioCentury Company Profiles for the biopharma industrySee details»
iOx Therapeutics Ltd. - Contacts, Employees, Board Members
Organization. iOx Therapeutics Ltd. Connect to CRM . Save . Summary. Financials. People. Signals & News. Similar Companies. Highlights. Employee Profiles 2. About. iOx Therapeutics …See details»
Threitolceramide 6 (Portage Biotech) - Drug Targets, Indications ...
Originator Organization. Portage Biotech, Inc. ... Merck Sharp & Dohme Corp. iOx Therapeutics Ltd. Startup. Drug Highest Phase Phase 1/2. First Approval Date-Regulation-Login to view …See details»
Jim Mellon-backed biotech to join Aim - Financial Times
Mar 21, 2016 Its first asset is iOx Therapeutics which is working on treatments using so-called natural killer T-cells to attack tumours. ... The company owns 60 per cent of iOx with the rest …See details»